IL-6 inhibitors effectively reverse post-infarction cardiac injury and ischemic myocardial remodeling via the TGF-β1/Smad3 signaling pathway.
TGFβ1/Smad3
interleukin 6
interleukin 6 inhibitor
myocardial infarction
rejuvenation
ventricular remodeling
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
13
03
2022
accepted:
17
06
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Approximately one in four myocardial infarctions occur in older patients. The majority of therapeutic advances are either not appropriate or not tested in elderly patients. The main reasons for deviating from the guidelines are justified concerns regarding the effectiveness of the recommended forms of therapy, fear of adverse drug reactions and ethical concerns. Targeting interleukin 6 (IL-6) for ventricular remodeling after cardiovascular damage is a feasible alternative to standard polypharmaceutics, but the underlying molecular mechanisms are not well understood. Continuous activation of the IL-6-associated cytokine receptor gp130 leads to cardiomyopathic hypertrophy. TGFβ1 is involved in forming fibrosis in various organs, and its overexpression can cause myocardial hypertrophy and fibrosis. Il-6 has been hypothesized to be indirectly involved in cardiac remodeling via the TGFβ1/Smad signaling transduction pathway. In the present study, a rat model of acute myocardial ischemia, IL-6 and IL-6 receptor blockers were injected directly into the necrotic myocardium. Changes in cardiac function, myocardial infarction area, myocardial collagen, necrotic myocardial fibrosis and levels of TGFβ1, IL-6 and MMP2/9 were quantified in myocardial tissue fibrosis by ELISA. The present study demonstrated that IL-6 stimulated myocardial fibrosis through the TGFβ1-Smad-MM2/9 signaling transduction pathway. Overall, this provided a solid foundation for understanding the relationship between IL-6 and ventricular remodeling.
Identifiants
pubmed: 35949328
doi: 10.3892/etm.2022.11513
pii: ETM-24-3-11513
pmc: PMC9353402
doi:
Types de publication
Journal Article
Langues
eng
Pagination
576Informations de copyright
Copyright: © Wang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Int J Cardiol. 2018 Nov 15;271:19-20
pubmed: 30482454
Cells. 2022 Apr 20;11(9):
pubmed: 35563692
Oncotarget. 2015 Sep 8;6(26):22822-35
pubmed: 26287605
Am J Cardiol. 2010 Aug 1;106(3):360-8
pubmed: 20643246
J Hepatol. 2020 Oct;73(4):882-895
pubmed: 32330605
Cardiovasc Res. 2010 Aug 1;87(3):424-30
pubmed: 20211866
Crit Care. 2010;14(2):201
pubmed: 20497611
Br Med Bull. 2004 Oct 19;70:71-86
pubmed: 15494470
Hypertension. 2018 Sep;72(3):549-558
pubmed: 30354762
Results Immunol. 2013 Dec 14;4:8-13
pubmed: 24707455
Front Pharmacol. 2021 Aug 24;12:745061
pubmed: 34504432
Immunity. 2006 Feb;24(2):179-89
pubmed: 16473830
Sci Rep. 2020 Jan 15;10(1):378
pubmed: 31942001
Arq Bras Cardiol. 2016 Jan;106(1):62-9
pubmed: 26647721
Evid Based Complement Alternat Med. 2019 Dec 14;2019:5832105
pubmed: 31915448
J Transl Med. 2008 Nov 27;6:72
pubmed: 19038040
Cell Cycle. 2009 Jan 1;8(1):11-7
pubmed: 19106608
JACC Cardiovasc Imaging. 2011 Jan;4(1):98-108
pubmed: 21232712
World J Cardiol. 2017 May 26;9(5):407-415
pubmed: 28603587
Lab Invest. 2016 Aug;96(8):839-52
pubmed: 27348628
Clin Cardiol. 2004 Jul;27(7):417-20
pubmed: 15298045
J Cell Physiol. 2010 Nov;225(3):846-54
pubmed: 20607798
Circ Res. 2004 Mar 5;94(4):514-24
pubmed: 14726476
Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G28-38
pubmed: 16901989
Eur J Intern Med. 2004 Dec;15(8):523-528
pubmed: 15668089
Int J Biol Sci. 2011;7(7):1056-67
pubmed: 21927575
Curr Transl Geriatr Exp Gerontol Rep. 2013 Dec;2(4):
pubmed: 24349878
BJGP Open. 2017 Oct 04;1(3):bjgpopen17X101013
pubmed: 30564675
J Mol Cell Cardiol. 2014 May;70:74-82
pubmed: 24321195
Arch Intern Med. 2003 Oct 27;163(19):2345-53
pubmed: 14581255
N Engl J Med. 2008 May 22;358(21):2205-17
pubmed: 18499565
J Histochem Cytochem. 2016 Mar;64(3):157-67
pubmed: 26747705
Hypertens Res. 2010 Jan;33(1):11-21
pubmed: 19911001
J Hepatol. 2013 May;58(5):1007-19
pubmed: 23183525
BMC Med. 2018 Sep 25;16(1):167
pubmed: 30249247
Drug Discov Today Dis Mech. 2007;4(3):185-196
pubmed: 18690295
J Am Coll Cardiol. 2016 May 24;67(20):2419-2440
pubmed: 27079335
Front Physiol. 2017 May 26;8:341
pubmed: 28603501
Pediatr Rev. 2019 Feb;40(2):60-70
pubmed: 30709972
Am J Transl Res. 2018 Dec 15;10(12):4082-4094
pubmed: 30662652
Annu Rev Physiol. 2004;66:29-48
pubmed: 14977395
Heart. 1999 Aug;82(2):192-8
pubmed: 10409535
FASEB J. 2003 Nov;17(14):2130-2
pubmed: 14500551
J Echocardiogr. 2019 Mar;17(1):10-16
pubmed: 30390189
Nat Rev Dis Primers. 2020 Mar 5;6(1):16
pubmed: 32139695
Gastroenterology. 2013 Dec;145(6):1323-33
pubmed: 23994200
BMC Fam Pract. 2015 Oct 14;16:129
pubmed: 26462820
Heart Fail Rev. 2014 Mar;19(2):173-85
pubmed: 23124941
EMBO J. 1997 Sep 1;16(17):5353-62
pubmed: 9311995
Iran J Basic Med Sci. 2019 Jun;22(6):643-649
pubmed: 31231492
Hepatology. 2014 Feb;59(2):483-95
pubmed: 23996730
J Comorb. 2018 Mar 08;8(1):9-15
pubmed: 29651408